대한뉴팜

Daehan New Pharm Practices 'V-3 UP' for Achieving GoalsSix-Hour Climb to Biro Peak on Odaesan Mountain... Awards Ceremony for 33 Outstanding Employees Held Daehan New Pharm (CEO Park Myung-rae) held the 'ATAT 2005 (Achieving Target All Together)' seminar and hiking event over two days on the 7th and 8th, with all employees participating to strengthen commitment to goal achievement, establish goal awareness, and activate sales. On the first day, the hike course started from Sangwonsa Temple on Odaesan Mountain and circled Biro Peak, with everyone completing the approximately 6-hour journey without incident. The evening gathering fostered team unity and was a lively affirmation of organizational strength. On the second day, an in-depth discussion on the strategies of each business unit for achieving goals in the second half of 2005 was held during the 'ATAT 2005 Achievement Seminar' aimed at leaping forward as a top-tier company. Based on the slogan "Let's Achieve Our Goals Together," the detailed execution goals of 'V-3 UP' (Volume up: achieving goals, Value up: creating value, Vision up: creating the future) were set to strengthen unity among all employees. This marked a spirited leap toward successful completion of 2005 and a fresh start for 2006. The event also included an awards ceremony for 33 outstanding employees, granted overseas training opportunities in Southeast Asia, and a special lecture titled "The Difference Between Professionals and Amateurs" delivered by lightning courier instructor Jo Tae-hoon emphasizing professional spirit.

In accordance with Article 26-3 and Article 34, Paragraph 4 of the Pharmaceutical Affairs Act and [Regulations on the Implementation of Drug Reevaluation (KFDA Notification)], reevaluation was conducted on [2 therapeutic groups of artificial perfusion agents, 22 sites, 141 items] and [4 other metabolic therapeutic groups, 55 sites, 848 items], and the results are hereby announced. Affected products include:Glizide Tablets (Gliclazide)Daien Capsules (Green Tea Powder, Ortho-Ciphen Powder)Bronase Tablets (Deoxyribonuclease, Bromelain) For inquiries related to this announcement: Responsible Department: Daehan New Pharm Development Division Contact: 02-3415-7857

Daehan New Pharm Co., Ltd. has newly launched the OTC packaging of Sancotec Tablet, a second-generation antihistamine tablet. The Sancotec Tablet (10T) is available for purchase at pharmacies and contains cetirizine hydrochloride, a widely used anti-allergic agent worldwide. It works by blocking histamine receptors and is highly effective for symptoms such as allergic rhinitis, allergic conjunctivitis, urticaria, and itching of the skin. The drug is rapidly absorbed for quick onset of effect and provides 24-hour efficacy with a simple once-daily one-tablet dose. As a second-generation antihistamine, it significantly reduces side effects like drowsiness and sedation. Itively targets H1 receptors without anticholinergic or antiserotonin effects, making it a safe formulation suitable for children aged 6 and above. For inquiries: Academic Development Department 02-3415-7839

Daehan New Pharm Co., Ltd. held the 21st Regular General Meeting of Shareholders on the 18th at the Hyangnam Pharmaceutical Complex in Hyangnam-myeon, Hwaseong-si, Gyeonggi-do. At the meeting, a cash dividend of 50 KRW (10%) was approved. Additionally, attorney Cho Yeon-ho was appointed as a new outside director, succeeding Dr. Yang Ji-won, who stepped down due to personal reasons. Daehan New Pharm's sales for 2004 reached 42.182 billion KRW, marking a strong growth of 17.4% compared to the previous year. Operating profit increased by 30.7% to 2.569 billion KRW due to sales growth, and ordinary profit rose by 5.7% to 1.463 billion KRW. However, net income for the year decreased by 8.4% to 904.8 million KRW due to an increase in deferred corporate taxes. CEO Park Myung-rae stated, "Daehan New Pharm will continue to maximize sales performance through continuous new product development and proactive customer-centered sales and marketing activities this year. We will also strengthen the accuracy and speed of operations by stabilizing the ERP system, making this year the first year for preparing to enter the 100 billion KRW sales era."

Daehan New Pharm Co., Ltd. has launched an intensive 18-day residential training program starting on the 26th, following the large-scale recruitment of new employees to strengthen their marketing, sales, and overseas business departments. Around 30 new and experienced employees,ed through document screening and interviews, including candidates for specialized task forces focusing on strategic product development, began the training at the Blue Monte Training Center in Anyang, Gyeonggi Province. The rigorous training schedule runs daily from 8:00 AM to 9:00 PM and covers basic pharmaceutical environment education, product knowledge, academic studies, and sales techniques. CEO Park Myung-rae, in his opening speech, emphasized that the company's future depends on the correct judgment and proactive actions of the new employees and urged them to devote themselves to the training with strong determination to become key players in self-realization and the company's leap to a top-tier organization.

Daehan New Pharm Officially Launches Redesigned Korean and English Company Website (www.dhnp.co.kr) in 2005 The newly revamped website maximizes visual promotional impact with elegant design while providing more detailed content about the company overall. It offers sector-specific health information for visitors, convenient product search features by business unit, an online application system for job applicants to build a talent pool, and an online purchasing system for partners, delivering diverse functionalities. Unique to Daehan New Pharm compared to typical pharmaceutical websites, an internal online café was introduced to activate staff clubs and enhance employee communication. The company has continuously supported employee clubs to promote a healthy corporate culture, and this new online café is expected to foster exchange between HQ and factory staff and contribute to developing a more progressive corporate culture. Additionally, Daehan New Pharm established a semi-SFA (Sales Force Automation) system integrating sales management and sales information sharing. This system allows sales staff to manage their basic sales activities directly online, while managers and executives can simultaneously monitor consolidated information to make decisions, creating a novel concept of an internal intranet. Daehan New Pharm's semi-SFA system achieves low cost and high efficiency in sales management with essential sales management modules tailored for individual sales staff, enabling easier adaptation than traditional complex systems used by other pharmaceutical companies. The remarkable aspect of this website redevelopment is the integration and operation of three online systems. Through this revamp, Daehan New Pharm aims to strengthen proactive online promotion and departmental online businesses, enhance sales capabilities, and realize organizational harmony, actively responding to pharmaceutical market changes for continuous growth. Meanwhile, since 2003, Daehan New Pharm has also operated a marketing website for obesity-related products called Diet Pharm (www.dietpharm.co.kr).

Daehan New Pharm Strengthens Specialization in Obesity Treatment Field Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) kicked off 2005 with the launch of new products including Fastin Tablet for obesity treatment and iCool Capsules for eye nutrition. At the New Year ceremony held at the Suwon Lavidol Resort with all employees in attendance, the company committed to achieving its sales goals for the year and making 2005 a year of corporate growth. Fastin Tablet contain phentermine hydrochloride, a drug approved by the US FDA for appetite suppression in patients with exogenous obesity. Daehan New Pharm has actively marketed a diverse portfolio of products in the fields of appetite suppressants, fat absorption inhibitors, thermogenesis promoters, and obesity treatment mesotherapy formulations. The launch of Fastin Tablet, expected to capture a significant market, is aimed at cementing the company’s position as a specialist pharmaceutical company in obesity treatment. The obesity treatment market was valued at approximately 50 billion KRW in 2004, and Daehan New Pharm anticipates capturing at least 15% of this market. Recognizing that many clinics show great interest in treating obesity patients but lack familiarity with patient engagement methods, the company plans to train obesity specialist coordinators and develop customer-centric marketing strategies.

Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) has newly launched 'Spo-K Plaster,' an arthritis and muscle pain treatment containing menthol, thereby entering the patch market. Each patch contains 30 mg of ketoprofen and features an added L-menthol component, providing a cooling sensation immediately upon application. Spo-K uses a non-irritating breathable nonwoven fabric, making it safe for patients with sensitive skin, and its enhanced adhesive technology ensures it adheres well to curved areas such as the knees and elbows. The innovative adhesive technology improves adhesion and significantly reduces the problem of edges curling, common in conventional products. Utilizing advanced Transdermal Drug Delivery System (TDDS) technology, the product targets pain areas directly, avoiding systemic side effects like liver toxicity and gastrointestinal disorders associated with oral administration. The current anti-inflammatory and analgesic patch market is dominated by Ketotop Plaster from Taepyeongyang Pharmaceutical and Kephentek Plaster from Jeil Pharmaceutical, forming approximately a 45 billion KRW market in 2005. Daehan New Pharm's new entry with Spo-K Plaster is expected to actively seek expansion in this market. Through this launch, Daehan New Pharm aims to revitalize the stagnating OTC market with diverse marketing strategies, enhance consumer recognition, and strengthen pharmacy sales. The company plans to balance herbal medicines and Western OTC products as part of their product strategy, using this opportunity as a springboard for invigorating pharmacy operations.

Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) held a celebration ceremony at its headquarters auditorium on October 19, marking its 20th anniversary. The event was attended by employees and executives who reaffirmed their commitment to transforming into a total healthcare group. The ceremony featured introductions to the company’s history, awards for long-term employees and outstanding workers, a ceremonial rice cake cutting, and commemorative speeches. Chairman Lee Wan-jin expressed gratitude to all partner companies and customers who have supported Daehan New Pharm with mutual trust and emphasized the importance of understanding the essence of the pharmaceutical industry to sustain the company’s longevity. He urged management to focus on nurturing talent and fulfilling the company’s role in contributing to the advancement of public health. Founded in 1984, Daehan New Pharm began with the production of veterinary medicines and has since expanded to establish state-of-the-art manufacturing facilities in the Hyangnam pharmaceutical complex. The company has built large-scale production lines for various pharmaceutical formulations, including traditional Korean herbal granules, as well as facilities and business units for health foods, beverages, and baby products, steadily progressing toward becoming a total healthcare group. During the ceremony, long-term service awards for 10 years of dedicated service were presented to Assistant Manager Lim Hee-taek and Assistant Manager Kim Seung-hwan from the veterinary production department.